This year ™s conference will continue to highlight cutting edge technologies, such as those offered by Affomix. These new technologies may enable point of care diagnostics, and response to treatment determinations, utilizing proteomics techniques on genomic-based platforms. Until now, there was no pipeline to produce the Affome?„?, a collection of monoclonal antibodies against all protein targets in the proteome, or a way to measure complex protein mixtures. stated Mike Snyder, Department Chair of Genetics at Stanford and a co-founder of Affomix. Rapid production of high quality monoclonal antibodies fused to nucleic acid backbones could provide a paradigm shift not only in proteomics research, but also in point of care diagnostics and personalized medicine, Snyder continued.

The conference is a one of kind of event offering the convergence of perspectives from thought leaders in genetics and medicine, the consumer product industry, the law, and the venture capital community, stated John Boyce, Conference Founder, Co-Founder of Delphi Bio, and President of DNA Like Me, Inc. We have chosen our speakers and subjects carefully, and thus created an unbiased forum where opinions (pro and con), can be voiced and where critical information can be disseminated, Boyce continued.

consumergeneticsconference/